FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1736100602> ?p ?o ?g. }

• W1736100602 endingPage "988" @default.
• W1736100602 startingPage "981" @default.
• W1736100602 abstract "Summary Large Phase 3 clinical trials for stroke prevention in atrial fibrillation (AF) have compared non-vitamin K antagonist oral anticoagulants (NOACs) against warfarin, with the edoxaban trial only recently reported. In the absence of head to head trials directly comparing these NOACs against each other, we compared the efficacy and safety of edoxaban to other agents by an indirect comparison analysis. We performed an indirect comparison analysis of edoxaban (2 dose strategies) against apixaban (1 dose), dabigatran etexilate (2 doses) and rivaroxaban (1 dose), for their relative efficacy and safety against each other. For high-dose edoxaban vs apixaban, there were no significant differences in efficacy endpoints, mortality, myocardial infarction and major bleeding. Apixaban was associated with less major or clinically relevant non-major bleeding (hazard ratio [HR] 0.79; 95% confidence interval [CI] 0.70–0.90) and gastrointestinal bleeding (HR 0.72; 95% CI 0.53–0.99). For dabigatran 110 mg twice daily, there were no significant differences in the main efficacy or safety endpoints. Dabigatran 150 mg bid was associated with lower stroke/systemic embolism (SE) (HR 0.75; 95% CI 0.56–0.99), stroke (HR 0.73; 95% CI 0.55–0.96) and haemorrhagic stroke (HR 0.48; 95% CI 0.23–0.99). There were no significant differences between high-dose edoxaban vs rivaroxaban for efficacy endpoints or mortality, but rivaroxaban had more major and/or clinically relevant non-major bleeding. When compared to low-dose edoxaban, apixaban was associated with lower stroke/SE (HR 0.70; 95% CI 0.55–0.89), stroke (HR 0.70; 95% CI 0.55–0.92) and ischaemic stroke (HR 0.65; 95% CI 0.50–0.89), but more major bleeding (HR 1.47; 95% CI 1.20–1.80). For dabigatran 110 mg bid, there were no significant differences in the efficacy endpoints, but dabigatran 110 mg bid had higher major (and gastrointestinal) bleeding. Dabigatran 150 mg bid and rivaroxaban were associated with lower stroke/SE and ischaemic stroke, but higher bleeding rates. In the present analysis, we have provided for the first time, comparisons of efficacy and safety of edoxaban against other NOACs. Notwithstanding the significant limitations of an indirect comparison analysis, some differential effects are evident with the NOACs for stroke prevention, allowing us to allow the prescriber a ‘choice’ to be able to fit the drug to the patient clinical profile (and vice versa). Note: The review process for this paper was fully handled by Christian Weber, Editor in Chief." @default.
• W1736100602 created "2016-06-24" @default.
• W1736100602 creator A5038405190 @default.
• W1736100602 creator A5058415494 @default.
• W1736100602 creator A5076999140 @default.
• W1736100602 creator A5078667862 @default.
• W1736100602 date "2014-01-01" @default.
• W1736100602 modified "2023-10-14" @default.
• W1736100602 title "Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation" @default.
• W1736100602 cites W1959701674 @default.
• W1736100602 cites W1972605974 @default.
• W1736100602 cites W1982179895 @default.
• W1736100602 cites W1990005204 @default.
• W1736100602 cites W1999468381 @default.
• W1736100602 cites W2005947177 @default.
• W1736100602 cites W2006947006 @default.
• W1736100602 cites W2035626182 @default.
• W1736100602 cites W2051565963 @default.
• W1736100602 cites W2071257976 @default.
• W1736100602 cites W2080111455 @default.
• W1736100602 cites W2083426277 @default.
• W1736100602 cites W2095647706 @default.
• W1736100602 cites W2096246254 @default.
• W1736100602 cites W2097854437 @default.
• W1736100602 cites W2114112775 @default.
• W1736100602 cites W2136489990 @default.
• W1736100602 cites W2141443241 @default.
• W1736100602 cites W2143034000 @default.
• W1736100602 cites W2149012794 @default.
• W1736100602 cites W2160625453 @default.
• W1736100602 cites W2162508946 @default.
• W1736100602 cites W2548706052 @default.
• W1736100602 cites W4297900745 @default.
• W1736100602 doi "https://doi.org/10.1160/th14-02-0118" @default.
• W1736100602 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24577485" @default.
• W1736100602 hasPublicationYear "2014" @default.
• W1736100602 type Work @default.
• W1736100602 sameAs 1736100602 @default.
• W1736100602 citedByCount "92" @default.
• W1736100602 countsByYear W17361006022014 @default.
• W1736100602 countsByYear W17361006022015 @default.
• W1736100602 countsByYear W17361006022016 @default.
• W1736100602 countsByYear W17361006022017 @default.
• W1736100602 countsByYear W17361006022018 @default.
• W1736100602 countsByYear W17361006022019 @default.
• W1736100602 countsByYear W17361006022020 @default.
• W1736100602 countsByYear W17361006022022 @default.
• W1736100602 crossrefType "journal-article" @default.
• W1736100602 hasAuthorship W1736100602A5038405190 @default.
• W1736100602 hasAuthorship W1736100602A5058415494 @default.
• W1736100602 hasAuthorship W1736100602A5076999140 @default.
• W1736100602 hasAuthorship W1736100602A5078667862 @default.
• W1736100602 hasConcept C126322002 @default.
• W1736100602 hasConcept C127413603 @default.
• W1736100602 hasConcept C164705383 @default.
• W1736100602 hasConcept C207103383 @default.
• W1736100602 hasConcept C2776301958 @default.
• W1736100602 hasConcept C2778661090 @default.
• W1736100602 hasConcept C2778810321 @default.
• W1736100602 hasConcept C2779161974 @default.
• W1736100602 hasConcept C2780290652 @default.
• W1736100602 hasConcept C2780638905 @default.
• W1736100602 hasConcept C2780645631 @default.
• W1736100602 hasConcept C42219234 @default.
• W1736100602 hasConcept C44249647 @default.
• W1736100602 hasConcept C71924100 @default.
• W1736100602 hasConcept C78519656 @default.
• W1736100602 hasConceptScore W1736100602C126322002 @default.
• W1736100602 hasConceptScore W1736100602C127413603 @default.
• W1736100602 hasConceptScore W1736100602C164705383 @default.
• W1736100602 hasConceptScore W1736100602C207103383 @default.
• W1736100602 hasConceptScore W1736100602C2776301958 @default.
• W1736100602 hasConceptScore W1736100602C2778661090 @default.
• W1736100602 hasConceptScore W1736100602C2778810321 @default.
• W1736100602 hasConceptScore W1736100602C2779161974 @default.
• W1736100602 hasConceptScore W1736100602C2780290652 @default.
• W1736100602 hasConceptScore W1736100602C2780638905 @default.
• W1736100602 hasConceptScore W1736100602C2780645631 @default.
• W1736100602 hasConceptScore W1736100602C42219234 @default.
• W1736100602 hasConceptScore W1736100602C44249647 @default.
• W1736100602 hasConceptScore W1736100602C71924100 @default.
• W1736100602 hasConceptScore W1736100602C78519656 @default.
• W1736100602 hasIssue "05" @default.
• W1736100602 hasLocation W17361006021 @default.
• W1736100602 hasLocation W17361006022 @default.
• W1736100602 hasOpenAccess W1736100602 @default.
• W1736100602 hasPrimaryLocation W17361006021 @default.
• W1736100602 hasRelatedWork W1972269502 @default.
• W1736100602 hasRelatedWork W1993190469 @default.
• W1736100602 hasRelatedWork W2040951791 @default.
• W1736100602 hasRelatedWork W2126328654 @default.
• W1736100602 hasRelatedWork W2167924766 @default.
• W1736100602 hasRelatedWork W2195369357 @default.
• W1736100602 hasRelatedWork W2741126211 @default.
• W1736100602 hasRelatedWork W2811048362 @default.
• W1736100602 hasRelatedWork W3173880122 @default.
• W1736100602 hasRelatedWork W4319019627 @default.
• W1736100602 hasVolume "112" @default.

• next